IR@PKUHSC  > 北京大学临床肿瘤学院  > 核医学科
学科主题临床医学
Characterization of an anti-human ovarian carcinomaxanti-human CD3 bispecific single-chain antibody with an albumin-original interlinker
Fang, M1; Zhao, R1; Yang, Z1; Zhang, Z1; Li, H1; Zhang, XT1; Lin, Q1; Huang, HL1
关键词Ovarian Carcinoma Human Cd3 Single-chain Bispecific Antibody
刊名GYNECOLOGIC ONCOLOGY
2004
DOI10.1016/j.ygyno.2003.10.032
92期:1页:135-146
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Obstetrics & Gynecology
研究领域[WOS]Oncology ; Obstetrics & Gynecology
关键词[WOS]MONOCLONAL-ANTIBODY ; T-CELLS ; TANDEM DIABODY ; TUMOR-THERAPY ; CANCER ; PHARMACOKINETICS ; COSTIMULATION ; IMMUNOTHERAPY ; TETRAVALENT ; COMBINATION
英文摘要

Objective. The objective of this study was to determine the properties of a single-chain bispecific antibody (scBsAb) against human ovarian carcinoma and to develop this agent for potential use in human ovarian cancer.

Methods. ELISA and FACS were performed to determine the antigen-binding properties of the scBsAb. Its abilities to retarget the preactivated human peripheral blood mononuclear cells (PBMCs) to human ovarian carcinoma cell line SKOV3 cells and mediate their lysis in vitro were performed by a colorimetric MTT-based assay. Nude mice bearing human SKOV3 tumor xenografts were used to study the distribution and imaging of the scBsAb. Its pharmacokinetics in vivo was also studied in naive BALB/c mice.

Results. The scBsAb showed nearly identical ligand binding properties at each site relative to the individual monovalent single-chain antibody prototype molecules and could bridge SKOV3 and human T cell line Jurkat, which expresses CD3 antigens on the surface of cells together. It can also retarget the pre-activated PBMCs to SKOV3 cells and mediated their lysis in vitro effectively. Imaging and distribution study demonstrated that the antibody could target the tumor. Its elimination in vivo corresponded to second-order kinetics with a terminal half-life time (t(1/2)beta) of 7.7 h.

Conclusion. This scBsAb with easy production and reasonable blood retention time should be developed for potential use in human ovarian cancer. (C) 2003 Elsevier Inc. All rights reserved.

语种英语
WOS记录号WOS:000189159600021
引用统计
被引频次:8[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50275
专题北京大学临床肿瘤学院_核医学科
作者单位1.Acad Sinica, Inst Genet & Dev Biol, Grp 102, Beijing 100101, Peoples R China
2.NW Sci Tech Univ Agr & Forestry, Dept Life Sci, Yangling 712100, Peoples R China
3.Beijing Canc Hosp, Dept Nucl Med, Beijing 100036, Peoples R China
推荐引用方式
GB/T 7714
Fang, M,Zhao, R,Yang, Z,et al. Characterization of an anti-human ovarian carcinomaxanti-human CD3 bispecific single-chain antibody with an albumin-original interlinker[J]. GYNECOLOGIC ONCOLOGY,2004,92(1):135-146.
APA Fang, M.,Zhao, R.,Yang, Z.,Zhang, Z.,Li, H.,...&Huang, HL.(2004).Characterization of an anti-human ovarian carcinomaxanti-human CD3 bispecific single-chain antibody with an albumin-original interlinker.GYNECOLOGIC ONCOLOGY,92(1),135-146.
MLA Fang, M,et al."Characterization of an anti-human ovarian carcinomaxanti-human CD3 bispecific single-chain antibody with an albumin-original interlinker".GYNECOLOGIC ONCOLOGY 92.1(2004):135-146.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Fang, M]的文章
[Zhao, R]的文章
[Yang, Z]的文章
百度学术
百度学术中相似的文章
[Fang, M]的文章
[Zhao, R]的文章
[Yang, Z]的文章
必应学术
必应学术中相似的文章
[Fang, M]的文章
[Zhao, R]的文章
[Yang, Z]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。